ZetrOZ Systems' Sam® Ultrasound Device Awarded As Top Wearable Tech Solution

ZetrOZ Systems, the creator of sustained acoustic medicine and the sam® wearable ultrasound medical device, has been named the Top Wearable Technology Solutions Provider for 2024 by Applied Technology Review. This platform and magazine focus on science and engineering-based solutions.

Applied Technology Review commended ZetrOZ Systems’ sam® line of devices for enabling patients to receive treatment wherever needed. The magazine highlighted the sam® X1 Device for its ability to provide untethered mechanobiology treatment without wires. The publication also noted that ZetrOZ Systems’ wearable ultrasound device functions automatically on the body for several hours a day, unlike treatments requiring scheduled surgeries or periodic injections.

"We’re pleased to see our innovation recognised with this award from a closely followed publication that tracks the forefront of developments in technology products," said George K. Lewis, biomedical engineer and founder and CEO of ZetrOZ Systems. "This will help get the word out to an even wider audience about our sam® devices and their record of successful treatment of soft tissue injury and accelerated injury healing."

ZetrOZ System’s wearable sam® devices offer long-duration, high-frequency, low-intensity ultrasound treatment for soft tissue injuries and joint arthritis. Depending on the injury, dosing typically ranges from one to four hours daily, over six to eight weeks.

The ZetrOZ Systems mechanobiological technology accelerates healing by increasing blood vessel diameters, improving blood flow, increasing oxygenated haemoglobin, and removing cytokine enzymes and cellular waste. This facilitates cellular regeneration and reduces pain.

FDA Clearance and Clinical Validation

The sam® line of devices is cleared by the U.S. Food & Drug Administration for treating conditions such as knee osteoarthritis, patellar and shoulder tendinopathy, and chronic back pain. The effectiveness of ZetrOZ Systems’ sustained acoustic medicine technology in treating these conditions is documented in 42 peer-reviewed publications and 20 Level 1-5 clinical studies.

Thousands of patients are treated with sam® devices every day, showcasing their widespread acceptance and effectiveness in medical practice.

About ZetrOZ Systems

ZetrOZ Systems is at the forefront of healing innovations in sports medicine, developing wearable bioelectronic devices to deliver sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on proprietary medical technology protected by 46 patents. It is the exclusive manufacturer and developer of the sam® product line, designed to treat acute and chronic musculoskeletal conditions.

For more information on ZetrOZ Systems, please visit www.samrecover.com.